Showing 1501-1510 of 2526 results for "".
- IDOC Unveils New Brand Identity and Platform for Optometristshttps://modernod.com/news/idoc-unveils-new-brand-identity-and-platform-for-optometrists/2484208/IDOC announced the launch of a refreshed brand identity and messaging platform designed to better serve independent optometrists. According to a news release, the revitalized brand aims to make independent ow
- Haag-Streit USA Unveils METIS 3D Digital Heads-Up Modulehttps://modernod.com/news/haag-streit-usa-unveils-metis-3d-digital-heads-up-module-at-aao-2025/2484194/Haag-Streit USA announced the launch of the METIS 3D Digital Heads-Up Module (METIS HU) at the American Academy of Ophthalmology (AAO) annual meeting in Orlando. Building on the METIS 900 ophthalmic microscope sys
- Biotech Healthcare Unveils Optiflex XTENSE Comfort Plus EDOF IOL in Europehttps://modernod.com/news/biotech-healthcare-unveils-optiflex-xtense-comfort-plus-edof-iol/2484159/Biotech Healthcare has launched the Optiflex XTENSE Comfort Plus: Full Visual Range EDOF IOL. The Optiflex XTENSE Comfort Plus, which was launched at the European Society of Cataract & Refractive Surgeons (E
- Genentech Unveils 5-Year Data for Susvimo: Long-Term Efficacy and Durability in Wet AMD Treatmenthttps://modernod.com/news/genentech-unveils-five-year-data-for-susvimo-long-term-efficacy-and-durability-in-wet-amd-treatment/2482915/Genentech announced new 5-year data from the phase 3 Portal study, which the company says reaffirms the long-term efficacy, safety, and durability of Susvimo (ranibizumab injection) in treating wet age-related macular degeneration (AMD). The fin
- Alcon Showcases Surgical Efficiency of Unity VCS Innovations at ASRS 2025https://modernod.com/news/alcon-showcases-surgical-efficiency-of-unity-vcs-innovations-at-asrs-2025/2482903/Alcon will showcase its latest clinical data and innovations at the 2025 American Society of Retina Specialists (ASRS) annual meeting, July 31 to August 2, in Long Beach, California. Attendees can explore Alcon’s latest surgical advancements through scientific presentations and hands-on dem
- Nicox and Kowa Sign Agreement for Exclusive Rights to Glaucoma Treatment NCX 470 in US and Unlicensed Territorieshttps://modernod.com/news/nicox-and-kowa-sign-agreement-for-exclusive-rights-to-glaucoma-treatment-ncx-470-in-us-and-all-unlicensed-territories/2482889/Kowa has gained exclusive rights to develop and commercialize NCX 470, Nicox’s nitric oxide (NO)-donating bimatoprost eye drop for the lowering of IOP in patients with glaucoma or ocular hypertension in the US and all other territories of the world excludin
- Study Finds Most Glaucoma Patients Unaware of Preservative-Free Treatment Optionshttps://modernod.com/news/60-of-glaucoma-patients-unaware-of-preservative-free-treatment-options-study-from-preservative-freedom-coalition/2482698/The Preservative Freedom Coalition announced the results of a new nationwide survey delving into the experience of glaucoma patients to identify opportunities for improved communication with their eye care providers. This comes as Monday kicked o
- Optos Unveils MonacoPro Ultra-Widefield and OCT Retinal Imaging Technologyhttps://modernod.com/news/optos-unveils-monacopro-ultra-widefield-and-oct-retinal-imaging-technology/2482688/Optos announced the launch of MonacoPro, the next generation ultra-widefield (UWF) SLO and spectral domain retinal imaging solution. Building on the legacy of Monaco, Optos said MonacoPro introduces features designed to elevate diagnostic precision and streamline workflow for eye care profes
- New Study Uncovers How Genes Influence Retinal Aging and Brain Healthhttps://modernod.com/news/new-study-uncovers-how-genes-influence-retinal-aging-and-brain-health/2482676/New research from the nonprofit biomedical research institution, The Jackson Laboratory (JAX), reveals that genetics play a key role in how the eye ages, with different genetic backgrounds influencing retinal aging in distinct ways. The study, published in
- Opus Genetics Receives FDA Agreement Under SPA for Phase 3 Trial of APX3330 in DRhttps://modernod.com/news/opus-genetics-receives-fda-agreement-under-spa-for-phase-3-trial-of-apx3330-in-diabetic-retinopathy/2482587/Opus Genetics announced it has reached agreement with the FDA on a Special Protocol Assessment (SPA) for a phase 3 clinical trial evaluating oral APX3330 for the treatment of moderate to severe non-proliferative diabetic retinopathy (NPDR).